Many people experience chronic pain or pain that lasts for an extended period. Experts are constantly researching new methods of pain relief and new medication options. One area of interest is the use of cannabis products as a method of pain relief.
A recent systematic review published in the Annals of Internal Medicine found that cannabis products might help treat chronic pain in the short term. However, medical professionals need to weigh this against the potential drawbacks of increased dizziness and sedation. It is also unclear whether or not these products are helpful in the long term.
Using cannabis as chronic pain relief
Chronic painTrusted Source lasts for months or longer, and millions of adults in the U.S. experience chronic pain. Because many people experience chronic pain, experts are constantly working to evaluate potential treatments and therapies. As experts continue to research the medicinal uses of cannabis, one area of interest is how doctors could use it to treat chronic pain.
CannabisTrusted Source is a plant, and people can use different plant portions to produce various products. The two main compoundsTrusted Source of cannabis are cannabidiol (CBD) and tetrahydrocannabinol (THC).
Some products contain both THC and CBD. The CBD portion does not cause mind-altering effects, while the THC portion causes the high people to experience when they use cannabis. Some of these related products are available in the U.S., while some are not. Currently, the Food and Drug AdministrationTrusted Source has approved using two medications that contain THC: Marinol and Syndros.
Effectiveness of cannabinoids for chronic pain
This systematic review sought “To evaluate the benefits and harms of cannabinoids for chronic pain.” The term Cannabinoids refers to compounds that contain both THC and CBD.
Researchers used several databases to collect the studies they reviewed. They included studies written in English that addressed the use of cannabis products as a treatment for chronic pain. Specifically, the study involved a follow-up or treatment time of four weeks or more. The analysis included placebo-controlled randomized controlled trials and cohort studies where the use of cannabis had a concurrent control group.
They included a total of 25 studies in their analysis. Researchers examined the products used in the studies and looked at the THC-to-CBD ratio. Did the product contain a high THC amount and a low CBD amount, was the amount about equal or did the product have a low THC amount and a high CBD amount?
The results of the review were somewhat lacking. The data was insufficient for some products to determine if they effectively treated chronic pain. However, researchers did discover some findings that supported the effectiveness of cannabis products:
- Synthetic oral products with a high THC-to-CBD ratio might contribute to short-term chronic pain relief.
- Sublingual extracted cannabis products with almost equal THC-to-CBD proportions might be associated with short-term improvements in chronic pain.
However, they found that people who use these products might also experience an increased risk for dizziness and sedation, which doctors will need to weigh against the potential benefits. Overall, they also found that experts need to conduct more studies about the long-term outcomes of cannabis use.